Please login to the form below
varenicline
This page shows the latest varenicline news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Champix and GSK’s Zyban cleared of causing neuropsychiatric side effects
The EAGLES study - published in The Lancet - backed the safety and efficacy of Pfizer's Chantix/Champix (varenicline) and GlaxoSmithKline's Zyban (bupropion) as well as nicotine replacement therapies in helping
Latest news
-
Study clears Pfizer’s Champix of serious risks
s Champix (varenicline). ... it is highly unlikely that varenicline has any significant adverse effects on cardiac or mental health.
-
FDA panel backs Sprout Pharma's 'female Viagra'
REMS are already in place for other 'lifestyle' drugs such as Vivus' Qsymia (phentermine/topiramate) for obesity and Pfizer's smoking cessation therapy Chantix (varenicline).
-
FDA votes to keep severe warning on Pfizer’s Chantix
An advisory panel to the agency voted against the removal this wee, k but agreed to revisit the issue once data from Pfizer's post-marketing study for Chantix (varenicline) is
-
Study ranks top pharma websites
The websites for Bayer's erectile dysfunction drug Levitra (vardenafil), Pfizer's smoking cessation drug Chantix (varenicline) and Lilly's erectile dysfunction drug Cialis (tadalafil) are among the most effective at
-
Data shows positive results for Champix
Results from a new study show smokers who took Pfizer's Champix (varenicline) were 33.5 per cent more successful in quitting smoking and abstaining during the last four weeks of
More from news
Approximately 1 fully matching, plus 16 partially matching documents found.
Latest Intelligence
-
On our best behaviour
Meanwhile, for non-nicotine pharmacotherapies with proven efficacy, such as Pfizer’s Champix (varenicline), their impact on effecting behaviour change depends almost entirely on reimbursement.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Diversity and inclusion in clinical trials: keeping up momentum
- 10 Important Advisor Questions: Placement of Your Product in the Current/Future Treatment Algorithm
- Merck announces partnerships worth $1.3bn with BenevolentAI and Exscientia
- EC approves Menarini Group’s Orserdu for advanced or metastatic breast cancer
- Eli Lilly files US lawsuits over ‘unlawful’ sales of Mounjaro counterfeits
- Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma
No results were found
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
